+ 34 986 812 316

ABIMAS. Biomedical Mass Spectrometry
Mannheim University of Applied Sciences, Paul-Wittsack-Str. 6, 68163 Mannheim, Germany

mass spectrometry imaging, mass spectrometry fingerprinting, epigenetic drugs


cell culture, mouse models of gastric carcinoma etc.


mass spectrometry imaging, mass spectrometry fingerprinting, liposomal drug formulations

Collaborations outside COST

GSK/Epinova/Cellzome, German Cancer Research Center (DKFZ) - Pediatric Oncology, University of Heidelberg - Clinical Pharmacology, HB Technologies (SME), Bruker Daltonics

Short description of ongoing research projects

Translational MS fingerprinting studies on HDAC inhibitor action

  1. improved MS imaging data analysis for analysis of HDACi action: Schwartz M, Meyer B, Wirnitzer B, Hopf C (2015). Standardized processing of MALDI imaging raw data for enhancement of weak analyte signals in mouse models of gastric cancer and Alzheimer's disease. Anal Bioanal Chem. 407(8): 2255-64.
  2. Becher I, Dittmann A, Savitski MM, Hopf C, Drewes G, Bantscheff M (2014). Chemoproteomics reveals time-dependent binding of histone deacetylase inhibitors to endogenous repressor complexes. ACS Chem Biol. 15;9(8):1736-46.
  3. Munteanu B et al. (2014). Label-free in situ monitoring of histone deacetylase drug target engagement by matrix-assisted laser desorption ionization-mass spectrometry biotyping and imaging. Anal Chem. 86(10):4642-7.
  4. Dawson MA et al. (2011). Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370):529-33.
  5. Bantscheff M*, Hopf C* et al (2011). Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 29(3):255-65. *equal contribution.
Other activities of potential interest to others

Bruker Rhine-Neckar Center for Mass Spectrometry Imaging and Fingerprinting; EU-FP7-MITIGATE (; BMBF Forschungscampus (

Cost UE